Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer

Gastro-esophageal Junction Cancer Clinical Trial

Official title:
An Open-label, Single-arm, Single-center, Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo®) in Subjects With Advanced or Recurrent Gastric Cancer

Status Recruiting

Clinical Trial Summary

This study was planned to evaluate the efficacy and safety of combination therapy of Immuncell-LC and nivolumab in patients with relapsed or advanced gastric adenocarcinoma or gastro-esophageal junction cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adenocarcinoma
Gastro-esophageal Junction Cancer

Clinical Trial Details

NCT number	NCT05053295
Study type	Interventional
Source	Gangnam Severance Hospital
Contact	Jae Yong Cho
Phone	82-2-2019-4601
Email	CHOJY@yuhs.ac
Status	Recruiting
Phase	N/A
Start date	July 2, 2021
Completion date	September 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00215514` - Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 0
Completed	`NCT00716157` - Incidence and Patterns of Nausea/Vomiting With Combined Chemotherapy and Radiation	N/A
Recruiting	`NCT06005493` - Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT01044511` - Quality of Life With Esophageal Stent Trial	N/A
Completed	`NCT01077999` - Chemoradiation and Panitumumab for Esophageal Cancer	Phase 2
Completed	`NCT02359968` - PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer	Phase 2
Completed	`NCT01084330` - Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer	Phase 2